H. C. Bennink

Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy.

H. C. Coelingh Bennink, H. Out, F. Rombout, 1996, Human reproduction update.

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.

H. Out, H. Bennink, B. Mannaerts, 1995, Human reproduction.

High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.

B. Fauser, H. C. Coelingh Bennink, N. Macklon, 1998, Human reproduction.

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.

H. C. Coelingh Bennink, H. Out, H. V. van Os, 1998, Human reproduction.

Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.

H. C. Coelingh Bennink, J. Cohen, H. Out, 1995, Human reproduction.